Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds
24 févr. 2020 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- - Company acquires rights to preclinical leads for Norovirus and Coronavirus therapeutics - - Proprietary platform technology will be used to...
Cocrystal Pharma Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference
11 févr. 2020 08h35 HE
|
Cocrystal Pharma, Inc.
– Presentation on Tuesday, February 18th at 11:30 AM ET – BOTHELL, WA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage...
Cocrystal Pharma to Present at the 12th Annual LD Micro Main Event
04 déc. 2019 08h00 HE
|
Cocrystal Pharma, Inc.
– Presentation on Tuesday, December 10th at 4:40 pm PST – BOTHELL, WA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage...
COCRYSTAL PHARMA, INC. PRICES $3,000,000 UNDERWRITTEN PUBLIC OFFERING
31 oct. 2019 09h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Oct. 31, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
COCRYSTAL PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
30 oct. 2019 16h45 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Oct. 30, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
Cocrystal Pharma Announces Abstract Accepted for Oral Presentation at the ISIRV: Options X for the Control of Influenza Conference
21 août 2019 08h05 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
International Stem Cell Corporation Completes Enrollment and Dosing in its Parkinson's Disease Clinical Trial
29 avr. 2019 08h30 HE
|
International Stem Cell Corporation
CARLSBAD, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQX: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage...
Cocrystal Pharma Announces Closing of Private Placement
11 mars 2019 08h30 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, March 11, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces Presentation at the RespiDART 2018: Frontiers in Drug Development Against Respiratory Viruses Conference
30 nov. 2018 08h00 HE
|
Cocrystal Pharma, Inc.
- Proprietary technology has the ability to fuel Cocrystal’s pipeline by effectively creating small molecule antiviral therapeutics that are safe, effective, convenient to administer and have the...
Cocrystal Pharma Announces Presentation of Preclinical Characterization Data of CC-42344 at the 6th ISIRV-AVG Conference
13 nov. 2018 11h50 HE
|
Cocrystal Pharma, Inc.
- Company’s novel, broad spectrum influenza antivirals specifically designed to be effective against all significant A strains of the influenza virus - - CC-43244, Company’s lead molecule has...